Abrdn Life Sciences Investors (HQL)
$12.95
Insights on Abrdn Life Sciences Investors
Increasing Revenue
Revenue is up for the last 3 quarters, 964.64 → 29.56M (in $), with an average increase of 83.4% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 33.80M → -11.45M (in $), with an average decrease of 133.9% per quarter
Vs KKR
In the last 1 year, Kkr & Co. L.p. has given 92.4% return, outperforming this stock by 96.8%
Vs APO
In the last 3 years, Apollo Asset Management Inc has given 74.1% return, outperforming this stock by 111.0%
Performance
- $12.91$13.03$12.95
0.31%
Downside
Day's Volatility :0.92%
Upside
0.61%
- $10.75$14.06$12.95
16.99%
Downside
52 Weeks Volatility :23.54%
Upside
7.89%
Returns
| Period | Abrdn Life Sciences Investors | Russel 2000 | Index (Russel 2000) |
|---|---|---|---|
3 Months | -5.0% | 0.0% | 0.0% |
6 Months | 13.1% | 0.0% | 0.0% |
1 Year | -5.48% | 2.2% | 2.2% |
3 Years | -36.89% | -23.0% | -23.0% |
Highlights
Market Capitalization | 359.7M |
Book Value | $16.12 |
Dividend Share | 1.3 |
Dividend Yield | 10.11% |
Earnings Per Share (EPS) | 0.79 |
PE Ratio | 16.65 |
PEG Ratio | 0.0 |
Profit Margin | 156.45% |
Operating Margin TTM | -48.76% |
Return On Assets TTM | -0.32% |
Return On Equity TTM | 1.28% |
Revenue TTM | 3.5M |
Revenue Per Share TTM | 0.13 |
Quarterly Revenue Growth YOY | 34.4% |
Gross Profit TTM | 3.0M |
Diluted Eps TTM | 0.79 |
Quarterly Earnings Growth YOY | -0.66 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
Technicals Summary
Sell
Neutral
Buy
Abrdn Life Sciences Investors is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Abrdn Life Sciences Investors | -2.74% | 13.1% | -5.48% | -36.89% | -19.95% |
 Blackstone Inc | -3.93% | 34.68% | 43.21% | 42.13% | 208.37% |
 Kkr & Co. L.p. | -4.05% | 76.33% | 89.6% | 74.14% | 301.37% |
 Blackrock, Inc. | -7.0% | 25.65% | 17.23% | -6.78% | 59.26% |
 Apollo Asset Management Inc | -0.62% | 38.48% | 82.9% | 106.71% | 248.01% |
 Brookfield Corp | -2.22% | 35.96% | 27.61% | -10.75% | 26.81% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Abrdn Life Sciences Investors | 16.65 | 16.65 | 0.0 | 0.0 | 0.01 | 0.0 | 0.1 | 16.12 |
Blackstone Inc | 67.56 | 67.56 | 1.75 | 4.85 | 0.21 | 0.09 | 0.03 | 9.63 |
Kkr & Co. L.p. | 23.95 | 23.95 | 1.3 | 4.8 | 0.09 | 0.02 | 0.01 | 25.83 |
Blackrock, Inc. | 19.49 | 19.49 | 2.46 | 41.27 | 0.14 | 0.03 | 0.03 | 264.96 |
Apollo Asset Management Inc | 13.74 | 13.74 | 1.37 | 7.74 | 0.32 | 0.02 | 0.02 | 22.27 |
Brookfield Corp | 66.18 | 66.18 | NA | 4.74 | 0.03 | 0.02 | 0.01 | 27.36 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Abrdn Life Sciences Investors | NA | $359.7M | -19.95% | 16.65 | 156.45% |
Blackstone Inc | Buy | $151.4B | 208.37% | 67.56 | 21.68% |
Kkr & Co. L.p. | Buy | $87.1B | 301.37% | 23.95 | 20.0% |
Blackrock, Inc. | Buy | $114.0B | 59.26% | 19.49 | 32.26% |
Apollo Asset Management Inc | Buy | $64.6B | 248.01% | 13.74 | 15.8% |
Brookfield Corp | Buy | $61.1B | 26.81% | 66.18 | 1.15% |
Corporate Announcements
Abrdn Life Sciences Investors Dividends March,2024
In the quarter ending March,2024. Abrdn Life Sciences Investors has declared dividend of $0.39
Read More
Company Information
tekla life sciences investors is a closed-ended equity mutual fund launched and managed by tekla capital management llc. the fund invests in public equity markets across the globe. it seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. the fund primarily invests in growth stocks of small cap companies. it employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. the fund benchmarks the performance of its portfolio against the nasdaq biotech index and the s&p 500 index. it was form
Organization | Abrdn Life Sciences Investors |
Employees | 0 |
CEO | Dr. Daniel R. Omstead M.S, Ph.D. |
Industry | Miscellaneous |
Discover More
Daseke Inc
$12.95
-1.3%
A Spac I Acquisition Corp
$12.95
-1.3%
Gamida Cell Ltd
$12.95
-1.3%
Palladyne Ai Corp
$12.95
-1.3%
Keyarch Acquisition Corp
$12.95
-1.3%
Connexa Sports Technologies Inc
$12.95
-1.3%
Semantix Inc
$12.95
-1.3%
Arrowroot Acquisition Corp-a
$12.95
-1.3%
Anfield Capital Diversified Alternatives Etf
$12.95
-1.3%